Metabolite Tales Blog

APRIL 10, 2024

Where data was publicly available, the routes of human metabolism for each of the drugs in this subset is listed in Table 1. It is proposed that the decreased clearance of the drug observed in patients may be due to depletion of GSH in this population [10]. Similar or higher metabolite levels were observed in rodents.

Small Molecule 59

Small Molecule FDA Approval FDA Pharmacokinetics 59

Drug Target Review

NOVEMBER 25, 2024

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. Additionally, we are preparing to launch several other trials over the coming months.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

DrugBank

JULY 24, 2024

Breaking New Ground with PROTACs One of the standout innovations in this space is the development of proteolysis-targeting chimeras, or PROTACs. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

LifeSciVC

JANUARY 16, 2024

Small molecule GLP1s? Whether trial design, execution, or otherwise, drug development even where there is precedent is a challenging road and should not be taken for granted. Additional trials (e.g.,

Small Molecule 143

Small Molecule Trials Therapies Disease 143

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning.

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

Broad Institute

NOVEMBER 2, 2023

Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drug development greatly increases our power to bring transformative medicines to cancer patients.” “We “Through this alliance, Broad and Bayer have done just that.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Target Review

SEPTEMBER 25, 2024

However, this will not be straightforward, given that non-oncogene resistance is driven by complex transcriptional networks, and the key drivers that determine how these mechanisms could be targets for drug development remain elusive. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions. References Sun D, et al. doi:10.1016/j.apsb.2022.02.002.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

Conversations in Drug Development Trends

APRIL 4, 2024

Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures. The post Demystifying the ICH M10 Bioanalytical Method Validation Guidelines appeared first on Worldwide Clinical Trials.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

Alta Sciences

FEBRUARY 10, 2025

Whether for a small or large molecule, we provide: Pharmacology, toxicology , and PK studies Analytical method development Formulation development and manufacturing Preclinical safety testing Clinical trial design Data reporting and documentation Want to know more before we get started?

Small Molecule 52

Small Molecule Clinical Trials Drug Development Trials 52

Drug Target Review

NOVEMBER 6, 2023

To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

DrugBaron

JANUARY 31, 2024

Unfortunately, it takes a decade or more to know whether your predictions in the drug discovery and development game were correct. The ways in which the financing framework for drug discovery and development works creates, in effect, a straightjacket that constrains and diminishes decision-making quality throughout the R&D process.

Pharma R&D 165

Pharma R&D Science Small Molecule Drugs 165

The Pharma Data

OCTOBER 25, 2020

NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease. . SOUTH PLAINFIELD, N.J. , Peltz , Ph.D.,

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52

The Premier Consulting Blog

NOVEMBER 20, 2024

For drugs with FDA Orphan Drug Designation (ODD), Breakthrough Therapy Designation (BTD), and EMA PRIority MEdicines designation (PRIME), all clinical, non-clinical, and CMC requirements are still required for regulatory approval, despite being on pathways for an expedited approval process.

Small Molecule 52

Small Molecule Drugs FDA Production 52

New Drug Approvals

APRIL 2, 2025

1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 This action and the agencys designations to expedite the drugs development and review underscore FDAs commitment to approving safe and effective alternatives to opioids for pain management. ESI-MS m/z calc.475.0922,

FDA 62

FDA Therapies Trials Treatment 62

Drug Target Review

JUNE 19, 2024

That would provide wonderful information as we think about then going into a first-in-human clinical trial. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

PPD

JUNE 27, 2024

In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on small molecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.

Treatment 52

Treatment Clinical Trials Clinical Research Small Molecule 52

KIF1A

JULY 22, 2023

Mutations that helped KIF1A process ATP also rescued synaptic development and movement symptoms. If these mutations change the structure of mutant KIF1A to help it perform better, this begs the question: Can we identify small molecules that fix the structure of mutant R9Q/R11Q KIF1A? Fisetin alleviates R9Q C.

Small Molecule 98

Small Molecule FDA Disease Treatment 98

Agency IQ

APRIL 19, 2024

Meet C3TI, FDA’s new clinical trial innovation hub On April 14, FDA announced that its Center for Drug Evaluation and Research (CDER) is launching a new clinical trial innovation hub, the CDER Center for Clinical Trial Innovation (C3TI). In particular, regulations in both the U.S.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Alta Sciences

JANUARY 31, 2024

This article will explore the purpose of all three types of analysis, and how they are used in early drug development. The crucial influence PK/PD can have on modeling and simulation decision-making and drug development risk management depends on the quality of data accessible at specific stages of drug development.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Drug Development Trials 52

The Pharma Data

NOVEMBER 26, 2020

As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS ® small molecule nanoparticle technology non-GMP lines. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! ” Prof. ” Prof.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

The Premier Consulting Blog

APRIL 18, 2024

This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product. As in all nonclinical drug development programs, the goal is to identify potential safety issues in humans. Can you identify a safe AND efficacious clinical dose?

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

The Premier Consulting Blog

MAY 31, 2023

As a cornerstone of the drug development process, nonclinical investigational new drug (IND)-enabling studies are essential for supporting first-in-human (FIH) dosing for novel therapeutics. Pharmacology A typical IND-enabling package includes information on the primary, secondary, and safety pharmacology of the drug.

Packaging 52

Packaging Pharmacokinetics Small Molecule Clinical Trials 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

JANUARY 10, 2021

(Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND) application with the U.S.

FDA 52

FDA Clinical Trials Small Molecule Therapies 52

The Premier Consulting Blog

AUGUST 8, 2024

Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch. It can simply start with a strategic assessment of your drug product. [i] 89 FR 61474.

Drugs 52

Drugs Pharmacokinetics FDA Production 52

Drug Target Review

MAY 1, 2024

At Zymeworks we apply a holistic approach to optimise each of the ADC components, leveraging insights gained from clinical trials and real-world clinical experience to inform the design of novel ADCs. Jamie Rich, PhD is Senior Director of Technology, ADC Therapeutic Development at Zymeworks Inc.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69

Sygnature Discovery

OCTOBER 10, 2023

For further information, visit www.sygnaturediscovery.com About Axol Bioscience Ltd Axol Bioscience use iPSCs to build more relevant models of human disease, to expand understanding and de-risk drug development.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

The Pharma Data

DECEMBER 10, 2020

Lexicon is currently enrolling patients with diabetic peripheral neuropathic pain in a Phase 2 proof-of-concept study of LX9211 and is preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia. The purpose of the designation is to expedite the timeline for bringing important new drugs to patients.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

The Pharma Data

DECEMBER 9, 2020

Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

NIH Director's Blog: Drug Development

JULY 20, 2017

Helping to fuel this optimism are preliminary results released this week from early-stage clinical trials of three next-generation, triple combination therapies that modulate the function of CFTR. According to preliminary data from one Phase 1 and two Phase 2 clinical trials reported by Vertex Pharmaceuticals Inc.,

Clinical Trials 52

Clinical Trials Small Molecule Disease Therapies 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

JANUARY 17, 2021

As Crooke explained, “With small molecules, if you make any chemical change, you have a new ballgame. That’s not the case with RNA-targeted drugs. Safety is critical in all clinical trials, but with ultra-rare diseases, even greater care is taken. Crooke, therefore, created n-Lorem Foundation to do that charitably.

Disease 52

Disease Clinical Trials Small Molecule Treatment 52

The Pharma Data

DECEMBER 14, 2020

. The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. Many drugs fail in clinical trials because of their low blood brain barrier permeability. Lantern’s A.I.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52